150 related articles for article (PubMed ID: 9273895)
21. Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin.
Agarwal NS; Rich DH
J Med Chem; 1986 Dec; 29(12):2519-24. PubMed ID: 3783611
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.
Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG
Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973
[TBL] [Abstract][Full Text] [Related]
23. Syntheses and biological activities of renin inhibitors containing statine analogues.
Nishi T; Saito F; Nagahori H; Kataoka M; Morisawa Y; Yabe Y; Sakurai M; Higashida S; Shoji M; Matsushita Y
Chem Pharm Bull (Tokyo); 1990 Jan; 38(1):103-9. PubMed ID: 2110866
[TBL] [Abstract][Full Text] [Related]
24. Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.
Luly JR; BaMaung N; Soderquist J; Fung AK; Stein H; Kleinert HD; Marcotte PA; Egan DA; Bopp B; Merits I
J Med Chem; 1988 Dec; 31(12):2264-76. PubMed ID: 3143009
[TBL] [Abstract][Full Text] [Related]
25. Renin inhibitors. Design of angiotensinogen transition-state analogues containing novel. (2R,3R,4R,5S)-5-amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic acid.
Thaisrivongs S; Pals DT; Kroll LT; Turner SR; Han FS
J Med Chem; 1987 Jun; 30(6):976-82. PubMed ID: 3295239
[TBL] [Abstract][Full Text] [Related]
26. Pepstatin analogues as novel renin inhibitors.
Guégan R; Diaz J; Cazaubon C; Beaumont M; Carlet C; Clément J; Demarne H; Mellet M; Richaud JP; Segondy D
J Med Chem; 1986 Jul; 29(7):1152-9. PubMed ID: 3543358
[TBL] [Abstract][Full Text] [Related]
27. Comparison of angiotensinogen and tetradecapeptide as substrates for human renin. Substrate dependence of the mode of inhibition of renin by a statine-containing hexapeptide.
Stammers DK; Dann JG; Harris CJ; Smith DR
Arch Biochem Biophys; 1987 Nov; 258(2):413-20. PubMed ID: 3314712
[TBL] [Abstract][Full Text] [Related]
28. Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.
Rosenberg SH; Plattner JJ; Woods KW; Stein HH; Marcotte PA; Cohen J; Perun TJ
J Med Chem; 1987 Jul; 30(7):1224-8. PubMed ID: 3298652
[TBL] [Abstract][Full Text] [Related]
29. Statine-containing dipeptide and tripeptide inhibitors of human renin.
Kokubu T; Hiwada K; Nagae A; Murakami E; Morisawa Y; Yabe Y; Koike H; Iijima Y
Hypertension; 1986 Jun; 8(6 Pt 2):II1-5. PubMed ID: 3087874
[TBL] [Abstract][Full Text] [Related]
30. New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site.
Luly JR; Bolis G; BaMaung N; Soderquist J; Dellaria JF; Stein H; Cohen J; Perun TJ; Greer J; Plattner JJ
J Med Chem; 1988 Mar; 31(3):532-9. PubMed ID: 3279206
[TBL] [Abstract][Full Text] [Related]
31. Structure-conformation relationships of synthetic peptide inhibitors of human renin studied by resonance energy transfer and molecular modeling.
Epps DE; Mao B; Staples DJ; Sawyer TK
Int J Pept Protein Res; 1988 Jan; 31(1):22-34. PubMed ID: 3284834
[TBL] [Abstract][Full Text] [Related]
32. Renin inhibitors. Synthesis of transition-state analogue inhibitors containing phosphorus acid derivatives at the scissile bond.
Allen MC; Fuhrer W; Tuck B; Wade R; Wood JM
J Med Chem; 1989 Jul; 32(7):1652-61. PubMed ID: 2661820
[TBL] [Abstract][Full Text] [Related]
33. The His-Pro-Phe motif of angiotensinogen is a crucial determinant of the substrate specificity of renin.
Nakagawa T; Akaki J; Satou R; Takaya M; Iwata H; Katsurada A; Nishiuchi K; Ohmura Y; Suzuki F; Nakamura Y
Biol Chem; 2007 Feb; 388(2):237-46. PubMed ID: 17261087
[TBL] [Abstract][Full Text] [Related]
34. Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.
Williams PD; Perlow DS; Payne LS; Holloway MK; Siegl PK; Schorn TW; Lynch RJ; Doyle JJ; Strouse JF; Vlasuk GP
J Med Chem; 1991 Mar; 34(3):887-900. PubMed ID: 2002469
[TBL] [Abstract][Full Text] [Related]
35. Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
Iizuka K; Kamijo T; Harada H; Akahane K; Kubota T; Umeyama H; Ishida T; Kiso Y
J Med Chem; 1990 Oct; 33(10):2707-14. PubMed ID: 2120440
[TBL] [Abstract][Full Text] [Related]
36. Peptide hairpins with strand segments containing alpha- and beta-amino acid residues: cross-strand aromatic interactions of facing Phe residues.
Roy RS; Gopi HN; Raghothama S; Gilardi RD; Karle IL; Balaram P
Biopolymers; 2005; 80(6):787-99. PubMed ID: 15895435
[TBL] [Abstract][Full Text] [Related]
37. X-ray analysis at 2.0 A resolution of mouse submaxillary renin complexed with a decapeptide inhibitor CH-66, based on the 4-16 fragment of rat angiotensinogen.
Dealwis CG; Frazao C; Badasso M; Cooper JB; Tickle IJ; Driessen H; Blundell TL; Murakami K; Miyazaki H; Sueiras-Diaz J
J Mol Biol; 1994 Feb; 236(1):342-60. PubMed ID: 8107115
[TBL] [Abstract][Full Text] [Related]
38. Design of potent substrate-analogue inhibitors of canine renin.
Hui KY; Siragy HM; Haber E
Int J Pept Protein Res; 1992 Aug; 40(2):152-60. PubMed ID: 1446972
[TBL] [Abstract][Full Text] [Related]
39. Peptide analogues of angiotensinogen. Effect of peptide chain length on renin inhibition.
Plattner JJ; Greer J; Fung AK; Stein H; Kleinert HD; Sham HL; Smital JR; Perun TJ
Biochem Biophys Res Commun; 1986 Sep; 139(3):982-90. PubMed ID: 3533075
[TBL] [Abstract][Full Text] [Related]
40. New potential renin inhibitors with dipeptide replacements in the molecule.
Winiecka I; Dudkiewicz-Wilczyńska J; Roman I; Paruszewski R
Acta Pol Pharm; 2010; 67(4):367-74. PubMed ID: 20635532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
